

PRIOR AUTHORIZATION REQUEST

Remodulin

Patient Inf	formation:	Kemodami		
Name:				
Member ID	D:		-	
Address:				
City, State	, Zip:			
Date of Bir				
	r Information:			
Name:				
NPI:				
Phone Nur	mber:			
Fax Numb	er			
Address:				
City, State	, Zip:			
	d Medication			
Rx Name:				
Rx Strengt	th			
Rx Quantit	ty:			
Rx Freque	ency:			
Rx Route	of			
Administra				
Diagnosis	and ICD Code:			
prescribed a quantities ca Upon receip	a medication for your an be provided. Plea of of the completed NA: Please no	efit requires that we review certain requests for coverage with the property patient that requires Prior Authorization before benefit coverage or coverage complete the following questions then fax this form to the toll-free need form, prescription benefit coverage will be determined based or other that supporting clinical documentation is required	overage of number list on the pla	f additiona sted below an's rules
	s the patient greater If no, no further ques	r than or equal to 18 years of age? stions.]	Yes	No
С		dication being prescribed by or in consultation with a pulmonologist or erience treating pulmonary hypertension? stions.]	Yes	No
	s the patient currently If no, skip to question	tly receiving the requested medication? on 8.]	Yes	No
4 D	Joes the patient hav	ve a previously approved prior authorization (PA) on file with the	Yes	No

[Note: If the patient does NOT have a previously approved PA on file for the requested

current plan?

PRIOR AUTHORIZATION REQUEST

	medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 8.]		
5	Has the patient been diagnosed with pulmonary arterial hypertension (PAH) as WHO Group 1? [If no, no further questions.]	Yes	No
6	Has the patient been established on therapy for at least 3 months? [If no, skip to question 9.]	Yes	No
7	Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [No further questions.]	Yes	No
8	Has the patient been diagnosed with pulmonary arterial hypertension (PAH) as WHO Group 1? [If no, no further questions.]	Yes	No
9	Will the patient be treated concomitantly with organic nitrates (for example, isosorbide mononitrate, isosorbide dinitrate, nitroglycerin)? [If yes, no further questions.]	Yes	No
10	Does the patient have NYHA Class II, III or IV symptoms? [If no, no further questions.]	Yes	No
11	Has documentation been submitted to confirm that the patient has had a right-heart catheterization (RHC)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
12	Has documentation been submitted to confirm that the patient has a mean pulmonary artery pressure (mPAP) GREATER THAN 25 mmHg? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
13	Has documentation been submitted to confirm that the patient has been evaluated with a baseline 6-minute walk test? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
14	Has documentation been submitted to confirm that the patient has experienced treatment failure with oral calcium channel blockers? ACTION REQUIRED: Submit supporting documentation. [NOTE: Examples of calcium channel blockers include amlodipine, nifedipine extended-release tablets.] [If yes, no further questions.]	Yes	No
15	Has documentation been submitted to confirm that the patient has a contraindication to oral calcium channel blockers? ACTION REQUIRED: Submit supporting documentation.	Yes	No



PRIOR AUTHORIZATION REQUEST

Please document the diagnoses, symptoms, and/or any other information important to this review:					
SECTION B: Physician Signature					
PHYSICIAN SIGNATURE	DATE				

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.